CDX2 and colorectal carcinoma: Another crucial consideration highlighted in the study conducted by Badia-Ramentol et al. is that the majority of scoring models utilized to assess CDX2 expression in CRC fail to consider tumor heterogeneity, simplistically categorizing tumors as either CDX2-positive, CDX2-moderately/weakly stained, or CDX2-negative based solely on the proportion of stained cells, despite the potential presence of heterogeneous staining intensity patterns within the tumor, which could impact prognosis [9].